Propranolol in Primary Progressive Aphasia
NCT: NCT06066710 · RECRUITING
Brief Summary
The purpose of this study is to find out how the language of people with Primary Progressive Aphasia is affected by Propranolol. Propranolol is not FDA approved for the treatment of Primary Progressive Aphasia. Propranolol is FDA approved for the treatment of heart conditions such as blood pressure. This research is being done because there are currently no drug treatment options for language impairments and anxiety often experienced by people with Primary Progressive Aphasia.
Frequently Asked Questions
What is Propranolol in Primary Progressive Aphasia?
Propranolol in Primary Progressive Aphasia is a clinical trial registered under NCT06066710. Current status: RECRUITING.
What is the status of NCT06066710?
The current status of NCT06066710 (Propranolol in Primary Progressive Aphasia) is: RECRUITING.
When did Propranolol in Primary Progressive Aphasia start?
Propranolol in Primary Progressive Aphasia started on 2025-01-13.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.